Evidence map›Paper›PMID 42665384›Full record

ArticleIn vivo (Athens, Greece)

The Phosphatidylinositol 3-Kinase (PI3K) Inhibitor Inavolisib Has Breast-cancer Synergy Combined With Recombinant Methioninase But Not on Normal Cells.

Jinsoo Kim, Qinghong Han, Shukuan Li, Yuta Miyashi, Tomoyuki Ishiguro, Michael Bouvet, Robert M Hoffman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jinsoo KimAntiCancer Inc., San Diego, CA, U.S.A.
Qinghong HanAntiCancer Inc., San Diego, CA, U.S.A.
Shukuan LiAntiCancer Inc., San Diego, CA, U.S.A.
Yuta MiyashiAntiCancer Inc., San Diego, CA, U.S.A.
Tomoyuki IshiguroAntiCancer Inc., San Diego, CA, U.S.A.
Michael BouvetDepartment of Surgery, University of California, San Diego, CA, U.S.A.
Robert M HoffmanAntiCancer Inc., San Diego, CA, U.S.A.; all@anticancer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe phosphatidylinositol 3-Kinase (PI3K) pathway is thought to be oncogenic in cancers when it is mutated at various sites. However, drugs targeting this mutated pathway have had only modest efficacy. Recently, a new inhibitor targeting the PI3K pathway, inavolisib (IVB), has been developed. In the present study, we determined whether IVB is synergistic with recombinant methioninase (rMETase) on breast-cancer cells compared to normal fibroblasts. MATERIALS AND

methodsCell viability was determined using the WST-8 cell-viability assay. The half-maximal inhibitory concentrations (IC

resultsThe IC

conclusionIVB had a very low IC

Indexed as

Breast NeoplasmsCarbon-Sulfur LyasesPhosphoinositide-3 Kinase InhibitorsAntineoplastic AgentsCell Line, TumorCell ProliferationCell SurvivalDrug SynergismFemaleFibroblastsHumansImidazolesIndazolesMCF-7 CellsOxazolesRecombinant Proteins2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidineAntineoplastic AgentsCarbon-Sulfur LyasesImidazolesinavolisibIndazolesL-methionine gamma-lyaseOxazolesPhosphoinositide-3 Kinase InhibitorsRecombinant ProteinsSulfonamidesbreast-cancer cellsHoffman effectHs-27 normal fibroblastsInavolisibMCF-7methionine addictionPI3K inhibitorrecombinant methioninasesynergy

Identifiers

PMID42665384
PMCPMC13531132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.